The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Beclometasone and formoterol inhaler (Fostair®) has been accepted for the symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. It should be used in patients for whom beclometasone and formoterol are appropriate choices of corticosteroid and long-acting beta2-agonist respectively, and for whom a metered dose inhaler is an appropriate delivery device.
Dapagliflozin (Forxiga®) has been accepted for restricted use in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as add-on combination therapy in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. The restriction limits use to triple therapy in combination with metformin and sulphonylurea, as an alternative to a dipeptidyl peptidase-4 (DPP-4) inhibitor.
Dapoxetine (Priligy®) has been rejected for the treatment of premature ejaculation in adult men aged 18 to 64 years. The manufacturer failed to make a submission and as a result it cannot be recommended.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« Drug Safety Update - June 2014||BNF for Children 2014-2015 »|